FZD7 and cancer: In addition to vantictumab, an oligopeptide Fz7-21 and a small molecule SRI37892 have been evaluated as a new Fzd7-targeting agent to disrupt the Wnt signaling pathway for inhibiting intestinal stem cell function and cancer progression (74, 75).